托珠单抗
细胞激素风暴
医学
病死率
细胞因子释放综合征
2019年冠状病毒病(COVID-19)
白细胞介素6
大流行
冠状病毒
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
病毒学
细胞因子
免疫学
重症监护医学
内科学
疾病
流行病学
传染病(医学专业)
作者
Alberto Boretti,Bimal K. Banik
摘要
Coronavirus disease 2019 (Covid-19) is the illness caused by severe acute respiratory syndrome coronavirus 2, first identified in Wuhan, China at the end of 2019. On March 11, 2020, the World Health Organization declared Covid-19 a global pandemic. The objective of this study is to determine the role of interleukin (IL) inhibitors in the treatment of Covid-19. By the majority of the reported clinical studies, the use of tocilizumab in Covid-19 infection appears promising in specific cases of the cytokine storm. Conflicting results prevent the recommendation of IL inhibitors against Covid-19 infection by many health organizations. However, many low-case fatality rate countries, with more advanced therapeutic approaches, uniformly include the use of tocilizumab in case of cytokine storms in addition to the standard treatment for severe cases which includes antivirals. Neglecting the other components is likely an explanation for the contradictory results found in the literature.
科研通智能强力驱动
Strongly Powered by AbleSci AI